Acerus Pharma
2486 Dunwin Drive
Mississauga
Ontario
L5L 1J9
Canada
Tel: 416-679-0771
Website: http://www.aceruspharma.com/
154 articles about Acerus Pharma
-
Acerus Pharma Hosting Key Opinion Leader Meeting on Unique Clinical Evidence of NATESTO® for Treatment of Hypogonadism
10/23/2019
Acerus Pharmaceuticals Corporation announced it will host a Key Opinion Leader meeting on new, unique clinical evidence supporting the expanded use of NATESTO® for the treatment of hypogonadism on Wednesday, October 30th in New York City.
-
BioSpace Global Roundup, Aug. 8
8/8/2019
Biopharma companies from across the globe share business and development updates. -
Acerus Reports Second Quarter and Year to Date Fiscal 2019 Financial Results
8/7/2019
Strengthened balance sheet with US$5 million subordinated secured loan facility in July
-
NATESTO® Spermatogenesis Study Final Results Accepted for Presentation at the American Society for Reproductive Medicine 75th Annual Scientific Conference
8/1/2019
Final study results accepted for “Late Breaking Presentation” on October 16, 2019
-
Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States
7/30/2019
Acerus Pharmaceuticals Corporation announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc.
-
Acerus to Report Second Quarter 2019 Financial Results and Host Investor Call
7/29/2019
Acerus Pharmaceuticals Corporation will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the market opens.
-
Acerus Congratulates US Partner Aytu Bioscience on Listing of NATESTO® on National Pharmacy Benefit Manager’s Formulary
7/24/2019
Acerus Pharmaceuticals Corporation announced that NATESTO® is now on formulary and covered nationwide by a leading national pharmacy benefit manager in the United States.
-
Acerus Announces Closing of US$5 Million Secured Term Loan
7/19/2019
Acerus Pharmaceuticals Corporation announced that it has entered into a US$5 million subordinated secured term loan facility with First Generation Capital Inc., a company affiliated with the Chairman of the Board of Directors of Acerus.
-
Acerus Provides Business Update on NATESTO® - July 10, 2019
7/10/2019
Acerus Pharmaceuticals Corporation announced an update relative to the Company’s NATESTO® business.
-
Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity
7/8/2019
Acerus Pharmaceuticals Corporation announced the acceptance of a new manuscript to the Journal of the Endocrine Society, describing how NATESTO® achieves similar symptom improvement, regardless of the degree of a patient’s baseline testosterone deficiency.
-
Acerus Provides Update On Avanafil Health Canada Submission
6/27/2019
Acerus Pharmaceuticals Corporation announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission for avanafil.
-
Acerus Reaches Mutual Agreement with Innovus Pharma to Terminate Distribution and License Agreement for UriVarx® in Canada
6/6/2019
Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF.
-
Acerus Signs License Agreement to Nasal Technology with University of Texas at Austin
5/30/2019
Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of testosterone.
-
Acerus Reports First Quarter 2019 Financial Results
5/13/2019
Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2019.
-
Acerus to Report First Quarter 2019 Financial Results and Host Investor Call
5/6/2019
Acerus Pharmaceuticals Corporation will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens.
-
Acerus Engages Paradigm Capital to Pursue Cannabinoid Opportunities
4/29/2019
Acerus Pharmaceuticals Corporation announced that it has engaged Paradigm Capital Inc. as its financial advisor to leverage its proprietary nasal delivery technology in cannabinoid applications through licensing, partnership agreements or other transactions with interested parties.
-
Acerus to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
4/24/2019
Acerus Pharmaceuticals Corporation announced that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.
-
Acerus Reports Fourth Quarter and Full Year 2018 Financial Results
3/5/2019
Acerus Pharmaceuticals Corporation reported its financial results for the three and twelve-month period ended December 31, 2018.
-
Acerus Files a New Drug Submission for Avanafil in Canada
3/4/2019
Acerus Pharmaceuticals Corporation announced that it has filed a New Drug Submission for Avanafil with Health Canada.
-
Acerus Provides Business Update on NATESTO®
2/27/2019
Acerus Pharmaceuticals Corporation announced two updates relative to the Company’s NATESTO® business.